ABSTRACT
Ovarian cancer is estimated to be the seventh leading cause of death from cancer among women worldwide. Large-scale trials are determine whether the combination of Transvaginal ultrasound (TVUS) plus CA-125 could provide acceptable levels of diagnostic accuracy for ovarian cancer screening. In a meta-analysis comparing the several morphological imaging modalities, Magnetic Resonance Imaging was of greatest incremental value in identifying ovarian cancer when the findings on TVUS were indeterminate. There are quite a bit more published data on ovarian cancer using in vitro Magnetic Resonance Spectroscopy (MRS). The findings from the investigations generally indicate a better distinction between malignant from benign ovarian lesions. The convergence pattern of the metabolite concentrations computed using the fast Pade transform for benign versus malignant ovarian cyst fluid. Even though there have been noteworthy results for ovarian cancer diagnosis, major problems remain that hinder broader use of in vitro MRS in the clinical area.
